<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05082064</url>
  </required_header>
  <id_info>
    <org_study_id>liver cirrhosis</org_study_id>
    <nct_id>NCT05082064</nct_id>
  </id_info>
  <brief_title>Observational Prospective Study.at the End of the Study the Patients Will be Classified According to PH,Serum Bicarbonate and Serum Sodium Into 6 Groups and Statistical Analysis Will be Performed Using Spss</brief_title>
  <official_title>Impact of Serum Bicarbonate and Electrolytes on Adverse Outcomes in Decompensated Cirrhotic Patients in Sohag University Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1-to identify the prognostic value of serum bicarbonate and serum electrolytes at time of&#xD;
      admission and their association with development of complications ,length of hospital stay&#xD;
      ,prognosis and mortality in hospitalized cirrhotic patient&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the purpose of this study will be explore the impact of data obtained for the arterial blood&#xD;
      gas parameters and serum bicarbonate and electrolytes at the time of hospital admission on&#xD;
      adverse clinical outcomes ,duration of length of hospital stay and mortality in patients with&#xD;
      cirrhosis .Furthermore incorporation these parameters into model of end stage liver disease&#xD;
      could help to improve the prognostic value of MELDscore in comparison to the prognostic value&#xD;
      of traditional equation of original MELD and child score&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 8, 2021</start_date>
  <completion_date type="Anticipated">March 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 8, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>will be ICU admitted</measure>
    <time_frame>from the day of admission to the day of discharge from hospital or death during hospitalization</time_frame>
    <description>will be admitted to ICU due to progression of the disease&#xD;
complications as shok,hepatorenal syndrome,severe infection,starting renal replacement therapy and icu intervention as mechanical ventilation using MELD score and child score depending on ABGparameters and serum electrolytes .</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>MELD score group A</arm_group_label>
    <description>MELD score :group A&lt;25</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MELD group B</arm_group_label>
    <description>Group B&gt;25</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MELD-PACO2 Group C</arm_group_label>
    <description>Group C&lt;25</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MELD -PACO2 Group D</arm_group_label>
    <description>Group D&gt;25</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MELD-BICARBONATE score Group E</arm_group_label>
    <description>Group E&lt;23</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MELD-BICARBONATE Group F</arm_group_label>
    <description>Group F&gt;23</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>arterial blood gases and serum electrolytes</intervention_name>
    <description>arterial bloog gases parameters serum potassium serum sodium serum calcium</description>
    <arm_group_label>MELD -PACO2 Group D</arm_group_label>
    <arm_group_label>MELD group B</arm_group_label>
    <arm_group_label>MELD score group A</arm_group_label>
    <arm_group_label>MELD-BICARBONATE Group F</arm_group_label>
    <arm_group_label>MELD-BICARBONATE score Group E</arm_group_label>
    <arm_group_label>MELD-PACO2 Group C</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        the study protocol will be approved by ethical committee of sohag university of medicine&#xD;
        written informed consent will be obtained from all participants&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        patients with confirmed diagnosis of cirrhosis (age &gt;18 years ) who will be admitted to&#xD;
        internal medicine department or will be admitted to intermediate care unit&#xD;
&#xD;
          -  willing and agree to be included in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients without evidence of cirrhosis&#xD;
&#xD;
          -  cirrhotic patients whom -younger than 18 years old&#xD;
&#xD;
               -  have diabetic ketoacidosis&#xD;
&#xD;
               -  with acute coronary syndrome&#xD;
&#xD;
               -  with fulminant liver failure&#xD;
&#xD;
               -  with heart failure&#xD;
&#xD;
               -  with organ transplantation&#xD;
&#xD;
               -  when arterial blood gases not be available&#xD;
&#xD;
               -  patient refusal&#xD;
&#xD;
               -  patient with HCC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heba allah Fadel, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical trial organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heba allah Fadel, Dr</last_name>
    <phone>01064462117</phone>
    <email>heba011213@med.sohag.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lotfy Hamed abo_ dahab, Prof</last_name>
    <phone>01003459739</phone>
  </overall_contact_backup>
  <results_reference>
    <citation>Scheiner B, Lindner G, Reiberger T, Schneeweiss B, Trauner M, Zauner C, Funk GC. Acid-base disorders in liver disease. J Hepatol. 2017 Nov;67(5):1062-1073. doi: 10.1016/j.jhep.2017.06.023. Epub 2017 Jul 3. Review.</citation>
    <PMID>28684104</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 10, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Heba Allah Fadel Abdel Rahman</investigator_full_name>
    <investigator_title>doctor,principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

